Skip to main content
Top
Published in: Rheumatology International 10/2008

01-08-2008 | Original Article

Management of cutaneous vascular complications in systemic scleroderma: experience from the German network

Authors: Ilka Herrgott, Gabriela Riemekasten, Nicolas Hunzelmann, Cord Sunderkötter

Published in: Rheumatology International | Issue 10/2008

Login to get access

Abstract

Major cutaneous vascular complications of systemic sclerosis (SSc) are secondary Raynaud’s phenomenon (RP) and digital ulcers. Even though SSc is a rare disease, timely and appropriate management of its vascular complications is mandatory for reducing the rate of major impairment. It should therefore be aware to physicians from different specialties. We evaluated the diagnostic and therapeutic approach toward secondary RP and ulceration in SSc patients at 28 German clinical centers at the time of initiation of the German network for Systemic Scleroderma (DNSS). We retrieved data via questionnaires and from the DNSS patient registry. Management of RP and ulcerations in SSc were heterogeneous at initiation of the network, reflecting a sometimes insufficient use of the diagnostic and therapeutic possibilities. As such, (1) calcium channel blockers were the first line therapy in most centers; but often in insufficient dosages, and (2) only 21.2% of patients with acral ulceration had received prostacyclins when recruited into the network. The sometimes insufficient care of vascular complications of SSc in Germany revealed the need for their standardized management, e.g. within a network for SSc and for consensus on a diagnostic or therapeutic algorithm.
Literature
1.
go back to reference LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22(4):675–694PubMedCrossRef LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22(4):675–694PubMedCrossRef
3.
go back to reference LeRoy EC (1989) The pathogenesis of systemic sclerosis. Clin Exp Rheumatol 7(Suppl 3):S135–S137PubMed LeRoy EC (1989) The pathogenesis of systemic sclerosis. Clin Exp Rheumatol 7(Suppl 3):S135–S137PubMed
4.
go back to reference Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F et al (1999) Different factors influencing the expression of Raynaud’s phenomenon in men and women. Arthritis Rheum 42(2):306–310PubMedCrossRef Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F et al (1999) Different factors influencing the expression of Raynaud’s phenomenon in men and women. Arthritis Rheum 42(2):306–310PubMedCrossRef
5.
go back to reference Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44(8):1841-1847PubMedCrossRef Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44(8):1841-1847PubMedCrossRef
6.
go back to reference Riemekasten G, Sunderkötter C (2006) Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii49–iii51CrossRef Riemekasten G, Sunderkötter C (2006) Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii49–iii51CrossRef
7.
go back to reference Sunderkötter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii33–iii35CrossRef Sunderkötter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii33–iii35CrossRef
8.
go back to reference Planchon B, de Faucal P, Essboui S, Grolleau JY (1986) A quantitative test for measuring reactivity to cold by the digital plethysmograph technique: application to 66 control subjects and 65 patients with Raynaud’s phenomenon. Angiology 37(6):433–439PubMedCrossRef Planchon B, de Faucal P, Essboui S, Grolleau JY (1986) A quantitative test for measuring reactivity to cold by the digital plethysmograph technique: application to 66 control subjects and 65 patients with Raynaud’s phenomenon. Angiology 37(6):433–439PubMedCrossRef
9.
go back to reference Pistorius MA, Planchon B, de Faucal P (1994) Plethysmographic cold test for diagnosis and evaluation of the severity of Raynaud’s phenomenon. Validation of the method by factorial analysis of correspondences in 541 patients. Int Angiol 13(1):10–14PubMed Pistorius MA, Planchon B, de Faucal P (1994) Plethysmographic cold test for diagnosis and evaluation of the severity of Raynaud’s phenomenon. Validation of the method by factorial analysis of correspondences in 541 patients. Int Angiol 13(1):10–14PubMed
10.
go back to reference Bukhari M, Herrick AL, Moore T, Manning J, Jayson MI (1996) Increased nailfold capillary dimensions in primary Raynaud’s phenomenon, systemic sclerosis. Br J Rheumatol 35(11):1127–1131PubMedCrossRef Bukhari M, Herrick AL, Moore T, Manning J, Jayson MI (1996) Increased nailfold capillary dimensions in primary Raynaud’s phenomenon, systemic sclerosis. Br J Rheumatol 35(11):1127–1131PubMedCrossRef
11.
go back to reference Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158(6):595–600PubMedCrossRef Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158(6):595–600PubMedCrossRef
12.
go back to reference Sarkozi J, Bookman AA, Lee P, Keystone EC, Fritzler MJ (1987) Significance of anticentromere antibody in idiopathic Raynaud’s syndrome. Am J Med 83(5):893–398PubMedCrossRef Sarkozi J, Bookman AA, Lee P, Keystone EC, Fritzler MJ (1987) Significance of anticentromere antibody in idiopathic Raynaud’s syndrome. Am J Med 83(5):893–398PubMedCrossRef
13.
go back to reference Hummers LK, Wigley FM (2003) Management of Raynaud’s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29(2):293–313PubMedCrossRef Hummers LK, Wigley FM (2003) Management of Raynaud’s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29(2):293–313PubMedCrossRef
14.
go back to reference Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66(6):754–763PubMedCrossRef Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66(6):754–763PubMedCrossRef
15.
go back to reference Merkel PA, Herln K, Martin RW, Anderson JJ, Mayes MD, Bell P et al (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 46(9):2410–2420PubMedCrossRef Merkel PA, Herln K, Martin RW, Anderson JJ, Mayes MD, Bell P et al (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 46(9):2410–2420PubMedCrossRef
16.
go back to reference Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19(9):1407–1414PubMed Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19(9):1407–1414PubMed
17.
go back to reference Veale DJ, Collidge TA, Belch JJ (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54(10):853–855PubMedCrossRef Veale DJ, Collidge TA, Belch JJ (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54(10):853–855PubMedCrossRef
18.
go back to reference Taylor MH, McFadden JA, Bolster MB, Silver RM (2002) Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 29(1):102–106PubMed Taylor MH, McFadden JA, Bolster MB, Silver RM (2002) Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 29(1):102–106PubMed
19.
go back to reference Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000953PubMed Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000953PubMed
20.
go back to reference Sunderkötter C, Riemekasten G (2006) Raynaud phänomen in der Dermatologie: Teil 2: Therapie. Hautarzt 57:927–938PubMedCrossRef Sunderkötter C, Riemekasten G (2006) Raynaud phänomen in der Dermatologie: Teil 2: Therapie. Hautarzt 57:927–938PubMedCrossRef
21.
go back to reference Distler M, Distler J, Ciurea A, Kyburz D, Muller-Ladner U, Reich K et al (2006) Evidence-based therapy of Raynaud’s syndrome. Z Rheumatol 65(4):285–289PubMedCrossRef Distler M, Distler J, Ciurea A, Kyburz D, Muller-Ladner U, Reich K et al (2006) Evidence-based therapy of Raynaud’s syndrome. Z Rheumatol 65(4):285–289PubMedCrossRef
22.
go back to reference Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000954PubMed Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000954PubMed
Metadata
Title
Management of cutaneous vascular complications in systemic scleroderma: experience from the German network
Authors
Ilka Herrgott
Gabriela Riemekasten
Nicolas Hunzelmann
Cord Sunderkötter
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 10/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0556-1

Other articles of this Issue 10/2008

Rheumatology International 10/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.